FMC Corporation functions as an agricultural science enterprise, delivering products for crop safeguarding, plant wellness, and professional pest and turf management. The ...
$0.82 주당
예상 EPS $0.11 · 매출 $872.18M · 9 명의 애널리스트
$0.82 주당
예상 EPS $1.10 · 매출 $1.12B · 9 명의 애널리스트
EPS $-0.12 · 매출 $791.40M
| 지표 | 최신 | 전년 대비YoY는 Year-over-Year(전년 대비)를 의미합니다. 최근 연도 값을 이전 연도 값과 비교하여 장기 추세의 강도를 보여줍니다. | 전분기 대비QoQ는 Quarter-over-Quarter(전분기 대비)를 의미합니다. 최근 분기를 직전 분기와 비교하여 단기 모멘텀 변화를 보여줍니다. |
|---|---|---|---|
| 매출고객에게 물건을 판매하여 청구서가 지급되기 전까지 들어온 총 금액입니다. 고객의 모든 카드 결제의 총합이라고 보시면 됩니다. (YoY는 올해를 작년 성과와 비교하며, QoQ는 최근 3개월을 이전 3개월과 비교합니다). | $3.5B | -18.3% | +14.3% |
| 순이익절대적인 최종 이익입니다. 회사가 모든 공급업체, 직원, 은행, 세무 당국에 비용을 지불하고 남은 실제 금액입니다. | $-2.2B | -758.7% | +33.7% |
| 매출총이익률기본적인 마진입니다. 100달러짜리 운동화를 판매한다면, 이 비율은 원료와 끈 비용을 지불한 직후의 이익이 가격의 얼마인지를 나타내며, 매장 임대료나 TV 광고 같은 비용은 제외됩니다. | +37.0% | -0.4% | +21.4% |
| 영업이익률본업의 효율성 점수입니다. 고객이 지불하는 1달러 중에서 제품을 만들고 모든 일상적인 회사 운영비(급여, 마케팅, 임대료 등)를 지불한 후 회사가 보유하는 금액을 나타냅니다. | -54.4% | -452.9% | -29.3% |
| 순이익률최종 이익 비율입니다. 모든 비용, 세금, 이자를 차감한 후, 매출 1달러 중 회사가 실제로 보유하는 정확한 액수입니다. | -64.6% | -906.6% | +42.0% |
| 잉여현금흐름기업 현금흐름의 핵심입니다. 일상적인 운영비를 지불하고 생존에 필요한 큰 설비(공장, 서버 등)에 투자한 후 남은 사용 가능한 실제 현금입니다. 배당금이나 자사주 매각에 사용될 수 있는 '자유' 현금입니다. | $-176.5M | -129.3% | +151.1% |
| FCF 마진궁극의 현금 전환율입니다. 일반 매출을 즉시 사용 가능한 현금으로 얼마나 잘 전환하는지를 나타냅니다. 비율이 높을수록 현금 창출 능력이 우수합니다. | -5.1% | -135.8% | +144.7% |
| 부채/자본재무 리스크 지표입니다. 차입금으로 구축된 자산과 주주의 자기자본 비율을 비교합니다. 높으면 레버리지가 크고 위험이 큽니다. | 202.7% | +160.2% | +2.3% |
| 유동비율12개월 생존 점검입니다. 현재 보유한 현금과 즉시 현금화 가능한 자산으로 1년 내 갚아야 할 즉시 청구서를 갚을 수 있는지를 비교합니다. 1 이상이면 당장 지급에 충분합니다. | 1.32x | -19.6% | +54.5% |
| 총자산회사의 절대적인 규모입니다. 계산대의 현금, 창고의 재고, 소프트웨어 특허, 공장 등 회사가 보유한 모든 가치 있는 자산을 합친 것입니다. | $9.7B | -16.9% | -2.9% |
| 지표 | 연간 (실적 vs 추정치) | 연간 서프라이즈 | 분기 (실적 vs 추정치) | 분기 서프라이즈 |
|---|---|---|---|---|
| EPS 서프라이즈 | -17.88 vs 2.95 | -706.0% | -1.48 vs 0.11 | -1430.0% |
| 매출 서프라이즈 | $3.5B vs $3.9B | -11.8% | $867.1M vs $872.2M | -0.6% |
| 날짜 | 임원 | 직책 | 증권 | 구분 | 주식 수 | 가격 |
|---|---|---|---|---|---|---|
| Jul 16, 2026 | BRONDEAU PIERRE R | director, officer: Chairman, CEO and President | Common Stock | A | 44 | — |
| Jul 16, 2026 | CORDEIRO EDUARDO E | director | Common Stock | A | 131 | — |
| Jul 16, 2026 | DAVIDSON CAROL ANTHONY | director | Common Stock | A | 83 | — |
| Jul 16, 2026 | Fortmann Kathy Lynn | director | Common Stock | A | 101 | — |
| Jul 16, 2026 | Johnson KLynne | director | Common Stock | A | 184 | — |
Operator: Ladies and gentlemen, thank you for joining us, and welcome to the First Quarter 2026 Earnings Call for FMC Corporation. This event is being recorded. I will now hand the conference over to Mr. Curt Brooks, Director of Investor Relations for FMC Corporation. Please go ahead. Curt Brooks: Good morning, and welcome to FMC Corporation's 2026 First Quarter Earnings Call. Today's prepared remarks will be provided by Pierre Brondeau, Chairman, Chief Executive Officer and President; and Andrew Sandifer, Executive Vice President and Chief Financial Officer. After prepared comments, we will take questions. Our earnings release and today's slide presentation are available on the FMC Investor Relations website, and the prepared remarks from today's discussion will be made available after the call. Let me remind you that today's presentation and discussion will include forward-looking statements that are subject to various risks and uncertainties concerning specific factors, including, but not limited to, those factors identified in our earnings release and in our filings with the Securities and Exchange Commission. Information presented represents our best judgment based on today's understanding. Actual results may vary based on these risks and uncertainties. Today's discussion and the supporting materials will include references to adjusted EPS, adjusted EBITDA, free cash flow, organic revenue growth and revenue, excluding India, all of which are non-GAAP financial measures. Please note that as used in today's discussion, CTPR means Chlorantraniliprole, earnings means adjusted earnings, EBITDA means adjusted EBITDA and sales refers to sales excluding India. A reconciliation and definition of these terms as well as other non-GAAP financial terms to which we may refer during today's conference call are provided on our website. With that, I will now turn the call over to Pierre. Pierre Brondeau: Thank you, Curt, and good morning, everyone. During the first quarter, we delivered results that exceeded the midpoint of our guidance range. In addition, we made good progress on our 2026 operational priorities, which are listed on Slide 3. These are strengthening the balance sheet through targeted debt reduction of approximately $1 billion, improving the competitiveness of our core portfolio, managing the post-patent transition for Rynaxypyr and supporting sales growth of new active ingredients, including Isoflex active, fluindapyr and Dodhylex active. I will start by providing an update on the progress of these 4 operational priorities, beginning with the debt reduction. We are continuing to target approximately $1 billion of debt paydown during 2026. The sale of our India commercial business continues to progress very well. We are in late stages with several potential buyers and expect to sign a definitive agreement in May. In addition, we are in advanced discussions with multiple potential partners regarding licensing of one of our new active …
| 이름 | 직함 | 보수 | 성별 | 출생 연도 | 상태 |
|---|---|---|---|---|---|
Pierre R. Brondeau | President, CEO & Non-Executive Chairman of the Board | USD 3,407,052 | — | 1958 | Active |
Andrew D. Sandifer | Executive Vice President & Chief Financial Officer | USD 1,581,180 | Male | 1970 | Active |
Jacqueline D. Scanlan | Executive VP & Chief Human Resources Officer | USD 1,019,172 | Female | 1973 | Active |
Thaisa Hugenneyer | Chief Sustainability Officer & Executive Vice President of Integrated Supply Chain | USD 906,542 | Female | 1980 | Active |
Vsevolod Rostovtsev | Executive Vice President & Chief Technology Officer | USD 670,315 | Male | 1975 | Active |
Shahid Saleem | Director & Head of Business Sustainability and Strategic Initiatives in Asia Pacific (APAC) | — | Male | — | Active |
Brian Angeli | Executive Vice President & President of North America | — | Male | 1977 | Active |
Curt Brooks | Director of Investor Relations | — | Male | — | Active |
Sara Velazquez Ponessa | Executive Vice President, General Counsel & Corporate Secretary | — | Female | 1972 | Active |
FMC NYSE: FMC reported second-quarter revenue of $841 million excluding India, below the low end of its guidance range, as cautious customer purchasing, unfavorable weather, low insect pressure and pricing pressure weighed on demand. However, adjusted EBITDA of $153 million exceeded the high end of management's guidance by 2%, aided by cost discipline and favorable quarter-specific items.
FMC Corporation (FMC) Q2 2026 Earnings Call Transcript
FMC reported second quarter earnings that missed revenue expectations. Management also guided to a lower revenue and earnings target for the year.
FMC's Q2 earnings beat estimates as cost gains offset weaker pricing and volumes. Revenues declined and 2026 sales guidance was cut.
FMC (FMC) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to earnings of $0.69 per share a year ago.
